Is Wegovy approved for obesity?
Yes, Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. It's indicated for use alongside reduced calorie diet and increased physical activity.[1]
How does Wegovy work for weight loss?
Wegovy is a GLP-1 receptor agonist that mimics a hormone to reduce appetite, slow gastric emptying, and increase feelings of fullness. Clinical trials showed average weight loss of 15-17% over 68 weeks in obese patients, compared to 2-3% with placebo.[1][2]
Who qualifies for Wegovy treatment?
Eligibility includes:
- BMI ≥30 kg/m² (obesity), or
- BMI ≥27 kg/m² (overweight) with comorbidities like cardiovascular disease or prediabetes.
It's not for type 1 diabetes or short-term weight loss. Providers assess based on individual health risks.[1]
Wegovy vs. Ozempic: Key differences for obesity
Both contain semaglutide, but Wegovy uses higher doses (up to 2.4 mg weekly) optimized for weight loss, while Ozempic (max 2 mg) is primarily for type 2 diabetes with weight loss as a secondary benefit. Wegovy carries obesity-specific labeling; off-label Ozempic use for weight loss is common but not FDA-approved for that purpose.[1][2]
Common side effects and patient concerns
Most patients experience nausea, diarrhea, vomiting, or constipation, often mild and decreasing over time. Serious risks include pancreatitis, gallbladder issues, or thyroid tumors (boxed warning). Long-term data shows sustained weight loss but potential muscle loss if not paired with exercise.[1][3]
Cost, access, and supply issues
Wegovy lists at about $1,350 per month without insurance. Coverage varies; Medicare covers it for obesity in some cases since 2024. Ongoing shortages have limited availability, pushing patients to compounded versions or alternatives.[4]
Patent status and generic timeline
Novo Nordisk holds patents on semaglutide formulations through 2032-2036 in the US, with challenges from competitors like Hims & Hers. No generics or approved biosimilars yet; exclusivity could extend via new formulations.[5]
[1]: FDA Label for Wegovy - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[2]: STEP Trials (NEJM) - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3]: Wegovy Safety Data - https://www.wegovy.com
[4]: Novo Nordisk Pricing - https://www.novomedlink.com/obesity/products/treatments/wegovy/pricing-and-access.html
[5]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/WEGOVY